FibroBiologics CFO Buys 70,000 Shares

Insider purchase signals confidence in biotech company's future

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

FibroBiologics Inc. (NASDAQ:FBLG) CFO Jason Davis purchased 70,000 shares of the company's stock on Monday, March 2nd, in a transaction valued at $28,700. The purchase increases Davis' direct ownership stake in the biotech firm to 70,000 shares.

Why it matters

Insider buying, especially by a company's CFO, is often viewed as a positive signal by investors, suggesting the executive has confidence in the firm's prospects and believes the stock is undervalued. This transaction could help boost investor sentiment around FibroBiologics as it continues developing its pipeline of cell therapy and regenerative medicine treatments.

The details

Davis acquired the 70,000 shares at an average price of $0.41 per share. Following the purchase, he now directly owns 70,000 shares in FibroBiologics, which has a current market capitalization of $26.31 million. The company's stock has traded between $0.22 and $1.53 over the past 52 weeks.

  • The share purchase was made on Monday, March 2, 2026.

The players

Jason Davis

The chief financial officer of FibroBiologics Inc.

FibroBiologics Inc.

A cell therapy and regenerative medicine company developing treatments for chronic diseases.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

What’s next

The company is expected to provide an update on its clinical pipeline and financial results in the coming weeks.

The takeaway

Insider buying by a company's CFO is often seen as a positive sign, suggesting the executive has confidence in the firm's future prospects. This transaction could help boost investor sentiment around FibroBiologics as it continues advancing its regenerative medicine treatments.